Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (amg 334) in migraine prevention: primary results of the strive trial

(2017) Peter J Goadsby et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Stewart Tepper et al.   LANCET NEUROLOGY

A Controlled Trial of Erenumab for Episodic Migraine

(2017) Peter J. Goadsby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context

(2017) Peter P. Toth et al.   JOURNAL OF MEDICAL ECONOMICS

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

(2016) Gillian D. Sanders et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Parametric Simulation of Headache Day Frequency Using A Negative Binomial Distribution: A Case Study of Erenumab in Episodic Migraine

(2016) JK Porter et al.   VALUE IN HEALTH

The Prevalence and Burden of Migraine and Severe Headache in the United States: Updated Statistics From Government Health Surveillance Studies

(2015) Rebecca C. Burch et al.   HEADACHE

Adherence to oral migraine-preventive medications among patients with chronic migraine

(2014) Zsolt Hepp et al.   CEPHALALGIA

The Prevalence, Impact, and Treatment of Migraine and Severe Headaches in the United States: A Review of Statistics From National Surveillance Studies

(2013) Todd A. Smitherman et al.   HEADACHE

Sex Differences in the Prevalence, Symptoms, and Associated Features of Migraine, Probable Migraine and Other Severe Headache: Results of the American Migraine Prevalence and Prevention (AMPP) Study

(2013) Dawn C. Buse et al.   HEADACHE

Cost and Predictors of Lost Productive Time in Chronic Migraine and Episodic Migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study

(2013) Daniel Serrano et al.   VALUE IN HEALTH

The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK

(2013) Anthony J. Batty et al.   JOURNAL OF MEDICAL ECONOMICS

The Evolution of a Migraine Attack - A Review of Recent Evidence

(2012) Andrew Charles   HEADACHE

Chronic Migraine Prevalence, Disability, and Sociodemographic Factors: Results From the American Migraine Prevalence and Prevention Study

(2012) Dawn C. Buse et al.   HEADACHE

The 2012 AHS/AAN Guidelines for Prevention of Episodic Migraine: A Summary and Comparison With Other Recent Clinical Practice Guidelines

(2012) Elizabeth Loder et al.   HEADACHE

Mapping from Disease-Specific Measures to Health-State Utility Values in Individuals with Migraine

(2012) Patrick J. Gillard et al.   VALUE IN HEALTH

Cost Effectiveness of Pharmacotherapy for the Prevention of Migraine

(2010) Junhua Yu et al.   CNS DRUGS

Prevalence of headache in Europe: a review for the Eurolight project

(2010) Lars Jacob Stovner et al.   JOURNAL OF HEADACHE AND PAIN

The Acute Treatment of Episodic and Chronic Migraine in the USA

(2009) ME Bigal et al.   CEPHALALGIA

Global prevalence of chronic migraine: A systematic review

(2009) JL Natoli et al.   CEPHALALGIA

Economic Burden of Transformed Migraine: Results From the American Migraine Prevalence and Prevention (AMPP) Study

(2009) Julie Munakata et al.   HEADACHE

The Burden of Migraine in the United States: Current and Emerging Perspectives on Disease Management and Economic Analysis

(2008) Elisabeth Hazard et al.   VALUE IN HEALTH